Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives

Journal of Cellular Physiology

Volumn 187, Issue 1, 2001, Pages 22-36

  Greco, Olga ^a   Dachs, Gabi U ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE G2; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; GANCICLOVIR; HORSERADISH PEROXIDASE; INDOLEACETIC ACID; THYMIDINE KINASE INHIBITOR;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TECHNOLOGY; GENE THERAPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYMES; FORECASTING; GENE THERAPY; HUMANS; PRODRUGS; PROTEIN BIOSYNTHESIS;

ANIMALIA; ARMORACIA RUSTICANA; HERPES;

EID: 0035123128     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H     Document Type: Review

References (179)

1. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine
2. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine deaminase gene therapies
3. Gap junctions: The "kiss of death" and the "kiss of life"
4. The bioactivation of 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)
5. Alkylation and cleavage of DNA by carbon-centered radical metabolites
6. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase
7. Antibody directed enzyme prodrug therapy: A pilot-scale clinical trial
8. Investigation of alternative prodrugs for use with E. coli nitroreductase in "suicide gene" approaches to cancer therapy
9. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells
10. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes virus simplex type 1 thymidine kinase gene-transfected tumor cells
11. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases
12. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis
13. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis
14. An HSV tk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice
15. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy
16. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
17. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
18. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
19. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite
20. Free-radical intermediates and stable products in the oxidation of indole-3-acetic acid
21. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer
22. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
23. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase
24. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy
25. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model
26. Differential activation of cyclophosphamide and ifosfamide by cytochrome P450 2B ans 3A in human liver microsomes
27. Intratumoral activation and enhanced chemotherapeutic effect of oxaphosphorines following cytochrome P450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
28. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
29. Combination gene therapy for liver metastasis of colon carcinoma in vivo
30. In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: Consequences for HSVtk/GCV anticancer gene therapy
31. Selective cell ablation in transgenic mice expressing E. coli nitroreductase
32. Oxidative metabolism of eyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation
33. 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
34. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments
35. The bystander effect-association of U-87 cell-death with ganciclovir-mediated apoptosis in nearby cells and lack of effect in athymic mice
36. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
37. Cure of mice bearing advanced plasma cell tumors with aniline mustard: The relationship between glucuronidase activity and tumor sensitivity
38. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gone requires host immune competence and leaves efficient memory
39. Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-1,4-dihydropyridine: A case for distinct proteolytic mechanism
40. Clinical protocl. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
41. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway
42. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
43. Targeting gene expression to hypoxic tumor cells
44. Bystander effect of purine nucleoside analogues in HSV-1tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues
45. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. 1997
46. Suicide gene therapy for plasma cell tumors
47. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
48. Suicide genes and bystander killing: Local and distant effects
49. Intercellular delivery of thymidine kinase prodrug activating enzyme by herpes simplex virus protein, VP22
50. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
51. Transport of 5-fluorouracil and uracil into human erythrocytes
52. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954
53. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase ganciclovir gene therapy
54. Horseradish peroxidase. III: Reaction with indole-3-acetic acid, light emission, and quantitative structure-activity relationships
55. Clinical protocol. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
56. The biochemistry and mechanism of action of acyclovir
57. Intercellular trafficking and protein delivery by a herpes virus structural protein
58. Intercellular trafficking of VP22-GFP fusion proteins
59. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase ganciclovir system in vitro
60. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene
61. Towards targeted "oxidation therapy" of cancer: Peroxidase-catalyzed cytotoxicity of indole-3-acetic acids
62. Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro
63. Oxidative activation of indole-3-acetic acids to cytotoxic species - A potential new role for plant auxins in cancer therapy
64. Bystander effect of the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck
65. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
66. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
67. Immune system in suicide gene therapy
68. Preclinical studies and clinical correlation of the effect of alkylating dose
69. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy
70. Gene-directed enzyme prodrug therapy: Quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase
71. Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect"
72. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine
73. Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma
74. Development of a novel enzyme/prodrug combination for gene therapy of cancer: Horseradish peroxidase/indole-3-acetic acid
75. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene
76. The macrophage - A novel system to deliver gene therapy to pathological hypoxia
77. Monitoring gene-therapy with cytosine deaminase-in vitro studies using tritiated 5-fluorocytosine
78. Selective inactivation of rat liver cytochromes P450 by 21-chlorinated steroids
79. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase
80. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model
81. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
82. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
83. Gap junction function and cancer
84. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
85. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
86. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus
87. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene
88. Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity
89. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
90. Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir
91. Tumor growth inhibitory nitrophenylaziridines and related compounds: Structure activity relationships
92. Radio-sensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
93. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts
94. Selective radiosensitization of 9L glioma cells in the brain transduced with double suicide fusion gene
95. A phase I/II study of herpes simplex type 1 thymidine kinase "suicide" gene therapy recurrent glioblastoma
96. A phase I/II doesescalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma
97. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-y1)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
98. A new cytotoxic, DNA interstrand cross-linking agent, 5-(aziridin-1-y1)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) by a nitroreductase enzyme in Walker carcinoma cells
99. The bioactivation of 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) - II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase
100. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant
101. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine
102. Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanism
103. cAMP stimulates the bystander effect in suicide gene therapy of human choriocarcinoma
104. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice
105. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma
106. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine
107. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer
108. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide
109. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine
110. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination
111. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy
112. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
113. Differential efficacy of suicide gene therapy by herpes simplex virus-thymidine kinase gene reflects the status of p53 gene in human esophageal cancer cells
114. The clinical rationale for S-phase radiosensitization in human tumors
115. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation
116. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
117. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
118. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
119. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
120. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12
121. Hypoglycemic action of indole-3-acetic acid by mouth in patients with diabetes mellitus
122. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
123. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase
124. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
125. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
126. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells
127. Self-immolative nitrogen mustard prodrugs for suicide gene therapy
128. Self-immolative anthracycline prodrugs for suicide gene therapy
129. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro
130. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
131. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
132. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model
133. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
134. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression
135. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase ganciclovir-mediated gene therapy
136. Molecular chemotherapy for breast cancer
137. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation
138. Antitumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V)
139. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
140. Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells
141. Intercellular delivery of functional p53 by the herpesvirus protein VP22
142. Peroxidase activity may play a role in the cytotoxic effect of indole acetic acid
143. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: Evidence of distant bystander effect
144. Production and characterization of a bicistronic Molooney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer
145. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
146. In vivo analysis of the "bystander effect": A cytokine cascade
147. Killing Epstein-Barr virus positive B lymphocytes by gene therapy: Comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase
148. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiatiosensitivity
149. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy
150. Gene transfer into humans-immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral transduction
151. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
152. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with herpes simplex thymidine kinase gene followed by ganciclovir
153. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model
154. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line
155. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene
156. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2
157. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study
158. Gene-directed enzyme prodrug therapy (GDEPT): Choice of prodrugs
159. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models
160. Gene therapy for glioblastoma multiform: In vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
161. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect
162. Selective augmentation of radiation effects by 5-fluorocytosine on murine B16(F10) melanoma cells transfected with cytosine deaminase gene
163. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches
164. Regional "pro-drug" gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma
165. Enhancement of the herpes simplex virus thymidine kinase ganciclovir bystander effect and its antitumour efficacy in vivo by pharmacologic manipulation of gap junctions
166. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
167. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
168. Systemic gene therapy of murine melanoma using tissue-specific expression of the hsvtk gene involves an immune component
169. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mono-nuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression
170. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes
171. Sensitisation of human carcinoma cells to the prodrug CB 1954 by adenovirus vector-mediated expression of E. coli nitroreductase
172. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
173. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm
174. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase
175. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: Induction of bystander killing in vitro and in vivo
176. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect
177. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines
178. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy
179. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice